Trastuzumab

證據等級: L5

預測適應症: 10 個

Trastuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Trastuzumab is an anti-HER2 monoclonal antibody whose standard use is in HER2-positive breast cancer. The TxGNN model predicts it may also be effective for progesterone-receptor (PR) positive breast cancer, with 36 clinical trials and 20 publications currently supporting this direction. Note: this predicted indication largely represents a molecular-subtype refinement (PR status as a stratification factor) within the already-recognized HER2-positive breast cancer population, rather than a mechanistically novel disease target.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer (referenced in evidence rationale text; no formal license text available in this evidence pack)
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.90%
Evidence Level	L1
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed structured mechanism-of-action data is not available in this evidence pack (original_moa is a data gap). Based on the information embedded in the trial/literature rationale, trastuzumab is an anti-HER2 (human epidermal growth factor receptor 2) monoclonal antibody, and its efficacy in HER2-positive breast cancer is well established as the current standard indication.

The predicted new indication — PR-positive breast cancer — is not a distinct mechanistic target. As stated directly in the evidence pack's repurposing rationale: "PR status is a stratification factor rather than a new mechanistic target; this represents a molecular-subtype extension of the existing indication." In practice, PR positivity frequently co-occurs with HER2 positivity (so-called "triple-positive" breast cancer, ER+/PR+/HER2+), and trastuzumab's HER2-targeted mechanism remains the operative driver of efficacy in this subgroup.

This is why the prediction is mechanistically plausible: multiple completed trials specifically enrolled HER2-positive patients who were also hormone-receptor positive (ER and/or PR positive), e.g. letrozole + trastuzumab (NCT00134680) and abemaciclib + trastuzumab ± fulvestrant (monarcHER, PMID 32353342), demonstrating that HER2-targeted therapy retains activity when combined with endocrine-pathway-directed agents in PR+/HER2+ disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04629846	Phase 3	Completed	517	Randomized, double-blind trial of QL1209 (pertuzumab biosimilar) + trastuzumab + docetaxel vs. reference pertuzumab + trastuzumab + docetaxel in ER/PR-negative, HER2+ early/locally advanced breast cancer — direct biosimilar/efficacy evidence for trastuzumab-based regimens
NCT00545688	Phase 2	Completed	417	4-arm randomized study of Herceptin (trastuzumab) + docetaxel ± pertuzumab in HER2-positive locally advanced/inflammatory/early breast cancer, evaluating pathological complete response
NCT00134680	Phase 2	Completed	33	Combination of letrozole + trastuzumab in ErbB2-positive AND estrogen/progesterone-receptor-positive metastatic breast cancer — directly relevant to the PR+/HER2+ subgroup
NCT03095352	Phase 2	Completed	76	Pembrolizumab + carboplatin vs. carboplatin alone in breast cancer patients with chest wall disease, including hormone-resistant ER+/PR+/HER2- and triple-negative subsets
NCT00005970	Phase 3	Completed	3436	Doxorubicin + cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for HER2-overexpressing node-positive or high-risk node-negative breast cancer
NCT01275677	Phase 3	Completed	3270	Adjuvant chemotherapy alone vs. chemotherapy plus trastuzumab in node-positive or high-risk node-negative HER2-low invasive breast cancer
NCT00667251	Phase 3	Completed	652	Taxane-based chemotherapy plus lapatinib vs. plus trastuzumab as first-line therapy for HER2/neu-positive metastatic breast cancer
NCT01785420	Phase 3	Recruiting	1100	Double-blind, randomized, placebo-controlled study of trastuzumab as short-duration preoperative therapy in HER2-neu-positive operable breast cancer
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab or placebo combined with neoadjuvant doxorubicin+cyclophosphamide followed by paclitaxel+trastuzumab+pertuzumab in early HER2-positive breast cancer
NCT02654119	Phase 2	Completed	20	Adjuvant cyclophosphamide, paclitaxel with trastuzumab in Stage I-II HER2/neu-positive breast cancer patients

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26874901	2016	RCT (Tier 1)	The Lancet. Oncology	ExteNET phase 3 trial: neratinib after trastuzumab-based adjuvant therapy improved outcomes in HER2-positive early breast cancer
37166817	2023	RCT	JAMA Oncology	WSG-TP-II: neoadjuvant endocrine therapy + trastuzumab + pertuzumab vs. de-escalated chemotherapy in HR-positive/HER2-positive early breast cancer
32353342	2020	RCT	The Lancet. Oncology	monarcHER phase 2 trial: abemaciclib + trastuzumab ± fulvestrant vs. chemotherapy + trastuzumab in hormone receptor-positive, HER2-positive advanced breast cancer
27179402	2016	RCT	The Lancet. Oncology	NeoSphere 5-year analysis: neoadjuvant pertuzumab + trastuzumab in HER2-positive breast cancer, showing sustained pathological complete response benefit
15894097	2005	Meta-analysis (Tier 1)	Lancet	EBCTCG overview of chemotherapy and hormonal therapy effects on recurrence and 15-year survival in early breast cancer
29117498	2017	Cohort (Tier 2)	NEJM	20-year risk of breast-cancer recurrence after stopping endocrine therapy at 5 years in ER-positive early breast cancer
31410192	2019	Cohort	Theranostics	Molecular portraits and trastuzumab responsiveness specifically in ER-positive, PR-positive, and HER2-positive ("triple-positive") breast cancer
35640077	2022	Guideline	J Clin Oncol	ASCO Guideline Update: systemic therapy recommendations for advanced HER2-positive breast cancer
34983437	2022	Retrospective cohort	BMC Cancer	Trastuzumab and fulvestrant combination therapy in hormone receptor- and HER2-positive advanced breast cancer
28945833	2017	Phase 2 trial	Annals of Oncology	WSG-ADAPT HER2+/HR- trial: 12-week neoadjuvant dual HER2 blockade (trastuzumab + pertuzumab) ± paclitaxel, de-escalation strategy

Germany Market Information

This drug currently holds no marketing authorizations in Germany in this evidence pack (market status: Not Marketed; total authorizations: 0). No license records are available to summarize dosage forms or approved indication text.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-HER2 monoclonal antibody); not a conventional cytotoxic chemotherapeutic per the evidence pack's rationale text
Myelosuppression Risk	Not directly characterized in this evidence pack. Trial evidence instead identifies cardiac toxicity, rather than myelosuppression, as the primary monitored risk specific to trastuzumab (see NCT01436604)
Emetogenicity Classification	Please refer to the package insert
Monitoring Items	Cardiac function (LVEF/echocardiogram), based on a dedicated cardiotoxicity-monitoring trial (NCT01436604); CBC and liver/renal function when trastuzumab is combined with cytotoxic chemotherapy partners
Handling Protection	Please refer to the package insert warnings and precautions; standard biologic/antibody handling applies to trastuzumab monotherapy, with cytotoxic-drug handling protocols relevant only when combined with conventional chemotherapy agents

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data are not available in this evidence pack (DDI query status: not found).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The PR-positive breast cancer indication is supported by evidence level L1 (multiple completed Phase 2/3 trastuzumab-based trials in HER2-positive/hormone-receptor-positive breast cancer), but it functions as a molecular-subtype extension of trastuzumab's existing HER2-positive breast cancer indication rather than a novel target — and a Blocking-severity safety data gap currently prevents formal safety pre-assessment.

To proceed, the following is needed:

Resolve Blocking gap DG001: obtain TFDA/official label warnings and contraindications (label PDF retrieval and parsing) — this is required before the candidate can enter S1 safety pre-assessment
Resolve High-severity gap DG002: obtain formal MOA documentation from DrugBank to support mechanistic-linkage analysis
Confirm PR-positivity biomarker stratification protocols, since current evidence treats PR status as a stratification factor rather than an independent therapeutic target
Clarify the drug's regulatory/market status in Germany, given 0 current authorizations and "Not Marketed" status
Run a proper drug-drug interaction query, as the current DDI check returned "not_found"

Additional note: This evidence pack also scored several other candidate indications for trastuzumab (e.g., normal breast-like subtype [L3], PR-negative breast cancer [L2], luminal A/B breast tumor [L2], and five rare non-breast tumor types [all L5, no supporting trials/literature, recommendation: Hold]). These are substantially weaker than the PR-positive breast cancer prediction and are not recommended for further action at this time.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.